Publicaciones en colaboración con investigadores/as de Mayo Clinic (54)

2022

  1. CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

    Cancers, Vol. 14, Núm. 2

  2. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  3. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Blood, Vol. 140, Núm. 11, pp. 1200-1228

  4. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  5. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1

  6. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024

  7. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1953-1963

  8. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1986-1998.e2

2021

  1. Authors reply to the letter to editor with regard to the article titled “Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping”

    Cytometry Part B - Clinical Cytometry

  2. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144

  3. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 142-155

  4. Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer

    Cancer Epidemiology Biomarkers and Prevention, Vol. 30, Núm. 9, pp. 1669-1680

  5. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 156-182

  6. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  7. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference

    Journal of Allergy and Clinical Immunology

  8. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 11, pp. 3918-3928